Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H14N6O10S2 |
| Molecular Weight | 466.404 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
InChI
InChIKey=UIMOJFJSJSIGLV-JNHMLNOCSA-N
InChI=1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7-/t5-,8+/m1/s1
| Molecular Formula | C12H14N6O10S2 |
| Molecular Weight | 466.404 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdfCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/4073864 | https://www.ncbi.nlm.nih.gov/pubmed/3065522 | https://www.ncbi.nlm.nih.gov/pubmed/3377459
Sources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdf
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/4073864 | https://www.ncbi.nlm.nih.gov/pubmed/3065522 | https://www.ncbi.nlm.nih.gov/pubmed/3377459
Carumonam is a monobactam antibacterial agent. It was highly active in vitro against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae and weakly active against Streptococcus pneumoniae, but it was not active against Staphylococcus aureus. The excellent activity of carumonam against Gram-negative bacteria is related to its high affinity for their penicillin-binding proteins. It is indicated for the treatment of urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. Another factor that contributes to the excellent activity of carumonam against Gram-negative bacteria is its resistance to beta-lactamases. Adverse effects of the carumonam were limited to phlebitis at the intravenous infusion site; bloody diarrhea.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
175 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
192.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
300.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
297.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
111 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
105 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
214 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
208 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
179 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1020 mg single, intravenous dose: 1020 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
493 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
783 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1302 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
56.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
113.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
230.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
107.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PROBENECID |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
117 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
186 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
602 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1112 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
186.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
156.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
330.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
287.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
170 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
147 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
300 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
293 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1020 mg single, intravenous dose: 1020 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.99 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PROBENECID |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.08 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.82% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
CARUMONAM plasma | Homo sapiens |
||
72% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: |
|
1 g 3 times / day multiple, parenteral Studied dose Dose: 1 g, 3 times / day Route: parenteral Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:30 GMT 2025
by
admin
on
Mon Mar 31 18:22:30 GMT 2025
|
| Record UNII |
486890PI06
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01DF02
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
||
|
WHO-VATC |
QJ01DF02
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
||
|
NCI_THESAURUS |
C260
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m3141
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
C79879
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
DB13553
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
100000081331
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
6540466
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
CARUMONAM
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
5508
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
87638-04-8
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
DTXSID3048312
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
C044145
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL1614658
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
SUB06152MIG
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
55486
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
486890PI06
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY | |||
|
521
Created by
admin on Mon Mar 31 18:22:30 GMT 2025 , Edited by admin on Mon Mar 31 18:22:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
